Inotuzumab ozogamicin in clinical development for acute lymphoblastic leukemia and non-Hodgkin lymphoma

B cell acute lymphoblastic leukemia (ALL) and non-Hodgkin lymphoma (NHL) frequently express CD19, CD20 and CD22 on the cell surfaces. Immunotherapeutic agents including antibodies and chimeric antigen receptor T cells are widely studied in clinical trials. Several antibody-drug conjugates (ADC) have...

Descripción completa

Detalles Bibliográficos
Autores principales: Aujla, Amandeep, Aujla, Ravijot, Liu, Delong
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2019
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6458768/
https://www.ncbi.nlm.nih.gov/pubmed/31011424
http://dx.doi.org/10.1186/s40364-019-0160-4

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6458768/
https://www.ncbi.nlm.nih.gov/pubmed/31011424
http://dx.doi.org/10.1186/s40364-019-0160-4

Ejemplares similares